Related Experiment Videos
Novel murine B-cell lymphoma/leukemia model to study BCL2-driven oncogenesis
Jules P P Meijerink1, Esther M M Van Lieshout, H Berna Beverloo
1Department of Pediatrics, Division of Oncology/Hematology, Erasmus MC Rotterdam-Sophia Children's Hospital, NL-3015GE Rotterdam, The Netherlands. j.meijerink@erasmusmc.nl
International Journal of Cancer
|January 13, 2005
Summary
The BCL-2 gene drives lymphoma and leukemia development in mice. This new model helps identify cooperating genes in BCL-2-driven cancers.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- The BCL-2 gene family plays a crucial role in hematopoietic malignancies like lymphoma and leukemia.
- Understanding genes that cooperate with BCL-2 is vital for deciphering leukemogenesis.
Purpose of the Study:
- To develop a murine model for studying genes that act synergistically with BCL-2 in causing lymphoma and leukemia.
- To investigate the role of BCL-2 family imbalance in tumorigenesis.
Main Methods:
- Established a BCL-2-driven murine B-cell lymphoma/leukemia model using FL5.12 cells.
- Transfected FL5.12 cells with BCL-2, BAX, or mutant BAX to create BCL-2 family imbalances.
- Injected transfectants into mice and monitored for leukemia development and progression.
Main Results:
- Mice injected with BCL-2-expressing cells developed leukemia, with disease incidence and latency dependent on BCL-2 family balance.
- Leukemic conversion involved secondary genetic changes and IL-3-responsive leukemia, independent of c-Myc or downstream apoptosis pathways.
- Leukemic clones maintained a normal DNA damage response, showing cell cycle arrest upon irradiation.
Conclusions:
- The developed mouse model effectively demonstrates BCL-2's role in driving lymphoma/leukemogenesis.
- This model serves as a valuable tool for identifying genes that cooperate with BCL-2 in cancer development.
- BCL-2 family imbalance is a key factor in the pathogenesis of these hematopoietic malignancies.